Skip to main content

Advertisement

Table 1 Patient and sample characteristics (n = 101)

From: Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations

  n (%)
Diagnostic category
 Solid tumors 65 (64)
 Hematologic conditions 36 (36)
Gender
 Male 60 (59)
 Female 41 (41)
Age (years)
 0–5 35 (34)
 6–12 30 (30)
 13–17 20 (20)
 ≥18 16 (16)
Samples tested (n = 120)
 Primary disease 85 (71)
 Relapse/refractory 35 (29)
Platform (n = 120)
 Cancer WES with transcriptome 63 (53)
 Cancer WES 19 (16)
 Constitutional WES 22 (18)
 Transcriptome only 3 (2)
 Targeted panel (467 genes) 13 (11)
Normal tissue source (n = 104)
 Blood 78 (74)
 Buccal swab 23 (23)
 Unaffected tissue 3 (3)
  1. WES whole-exome sequencing